Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-014 (Triptorelin) in Advanced Prostate Cancer
NCT06795191Phase 3Withdrawn
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Foresee Pharmaceuticals. Primary endpoints: Percentage of patients achieving castrate serum testosterone levels (< 50 ng/dL) at Day 28 and Percentage of patients maintaining castrate serum testosterone levels (< 50 ng/dL) at Week 48. Planned start Jun 2025; status: withdrawn.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06795191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795191.